OverviewSuggest Edit

Q BioMed is a biomedical acceleration and development company, focusing on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89, a radiopharmaceutical therapeutic for the treatment of bone cancer pain, Man-01, a solution for the treatment of primary open-angle glaucoma, and more.
TypePublic
Founded2013
HQNew York, NY, US
Websiteqbiomed.com

Latest Updates

Revenue (FY, 2020)$30 K
Share Price (Oct 2021)$0.6(-1%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Q BioMed

Rick Panicucci

Rick Panicucci

Director and Advisor, Pharmaceutical Development
Kristin Marvin Keller

Kristin Marvin Keller

Chief Commercial Officer
William Rosenstadt

William Rosenstadt

General Counsel and Director
Denis D Corin

Denis D Corin

CEO and Chairman
Show more

Q BioMed Office Locations

Q BioMed has an office in New York
New York, NY, US (HQ)
366 Madison Ave 3rd floor
Show all (1)

Q BioMed Financials and Metrics

Q BioMed Revenue

Q BioMed's revenue was reported to be $30 k in FY, 2020
USD

Revenue (FY, 2020)

30.0k

Gross profit (FY, 2020)

(296.0k)

Gross profit margin (FY, 2020), %

(986.7%)

Net income (FY, 2020)

(13.5m)

Market capitalization (18-Oct-2021)

15.4m

Closing stock price (18-Oct-2021)

0.6

Cash (30-Nov-2020)

177.1k

EV

15.4m
Q BioMed's current market capitalization is $15.4 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

30.0k

Cost of goods sold

326.0k

Gross profit

(296.0k)

Gross profit Margin, %

(987%)
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

313.0k15.0k15.0k

Cost of goods sold

34.7k158.5k

Gross profit

(19.7k)(143.5k)

Gross profit Margin, %

(131%)(957%)
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

12.6k131.4k1.5m824.8k2.7m172.6k177.1k

Prepaid Expenses

2.5k12.5k17.7k46.3k

Current Assets

12.6k131.4k1.5m827.3k2.7m190.3k223.5k

Total Assets

12.6k131.4k1.5m827.3k3.2m640.3k623.5k
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

17.2k12.6k31.4k3.4k715.0100.0240.9k163.0k138.0k313.3k1.4m2.5m2.3m786.9k1.3m178.7k301.7k740.6k3.0m1.3m

Accounts Receivable

11.5k12.3k

Prepaid Expenses

18.9k10.0k4.5k5.0k2.5k2.5k8.1k28.5k28.5k57.2k172.8k134.0k

Current Assets

17.2k12.6k31.4k3.4k19.6k100.0240.9k148.0k317.8k2.5m2.3m789.4k1.3m207.3k330.2k797.8k3.2m1.5m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(38.0k)(1.1m)(7.2m)(14.5m)(9.3m)(10.3m)(13.5m)

Depreciation and Amortization

50.0k50.0k

Inventories

(324.0k)

Accounts Payable

699.090.1k439.1k(34.4k)(71.3k)1.4m569.2k
Quarterly
USDQ1, 2014

Financial Leverage

1 x
Show all financial metrics

Q BioMed Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Q BioMed Online and Social Media Presence

Embed Graph

Q BioMed News and Updates

Q BioMed Signs Distribution Agreement with isoSolutions for the Sales of Strontium89 in Canada

NEW YORK, Aug. 10, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has recently entered into an exclusive distribution agreement with isoSolutions Marketing & Management Inc., a well-known distributor in Canada providing...

Q BioMed Signs License Agreement with Clionix for the Distribution and Sales of Strontium89 in Europe and Middle East

NEW YORK, July 12, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has recently entered into an exclusive license agreement with Clionix, a reputable distributor in Europe and the Middle East. Clionix is an authorized...

Q BioMed Awarded Federal Supply Contract for Strontium89 with U.S. Department of Defense and Veterans Affairs

NEW YORK, March 2, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has signed an agreement for Strontium89 (Strontium Chloride Sr-89 Injection, USP) to be included on the Federal Supply Schedule ("FSS"). The agreement provides...

Q BioMed Expands Strontium89 Reach Through Agreement with UroGPO, the Largest Group Purchasing Organization for Independent Urology Clinics in the US

NEW YORK, Feb. 1, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has been awarded a contract with UroGPO, the largest Group Purchasing Organization for urology private practice clinics in the US, whose members represent 650...

Q BioMed, Inc. CEO Discusses Recently Announced International Market Authorizations and Expansion in to South and Central America and Asia for Q BioMed’s Strontium89, its FDA Approved Drug for the Non-Opioid Treatment of Metastatic Cancer in the Bone

In addition, Corin discusses all the of the potential uses for MAN-19, a clinical grade therapeutic intended to treat complications caused by COVID-19, from SARS-Cov-2 to the seasonal flu. MAN-19 will be used as an intervention that could improve outcomes in the current COVID-19 pandemic around the …

Q BioMed, Inc. CEO Discusses Recently Announced Global Distribution Partnership with Caligor Coghlan Pharma Services in Audio Interview with SmallCapVoice.com

AUSTIN, Texas, July 09, 2020 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (“SCV”) today announces the availability of a new interview with Q BioMed Inc. (“the Company”) (OTCQB: QBIO), a commercial stage biotech company, CEO Denis Corin, who discusses the development of the Company’s exclusive Named…
Show more

Q BioMed Frequently Asked Questions

  • When was Q BioMed founded?

    Q BioMed was founded in 2013.

  • Who are Q BioMed key executives?

    Q BioMed's key executives are Rick Panicucci, Kristin Marvin Keller and William Rosenstadt.

  • What is Q BioMed revenue?

    Latest Q BioMed annual revenue is $30 k.

  • Who are Q BioMed competitors?

    Competitors of Q BioMed include Neuraxpharm, ViiV Healthcare and Medytox.

  • Where is Q BioMed headquarters?

    Q BioMed headquarters is located at 366 Madison Ave 3rd floor, New York.

  • Where are Q BioMed offices?

    Q BioMed has an office in New York.

  • How many offices does Q BioMed have?

    Q BioMed has 1 office.